

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number
WO 00/72820 A2

(51) International Patent Classification⁷: A61K 9/107,
31/08, A61P 23/00

ME14 5UW (GB). HORDER, Rodney, L. [GB/GB];
Grace Cottage, The Street, Hartlip, Kent ME9 7TG
(GB). WITHERS, Brian, C. [GB/GB]; 21 Sandy Mount,
Bearstead, Maidstone, Kent ME14 4PJ (GB).

(21) International Application Number: PCT/US00/14502

(22) International Filing Date: 25 May 2000 (25.05.2000)

(74) Agents: WOODWORTH, Brian, R. et al.; Dept. 377
Bldg. AP6D-2, 100 Abbott Park Road, Abbott Park, IL
60064-6050 (US).

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AU, CA, JP, US.

(30) Priority Data:
9912446.3 27 May 1999 (27.05.1999) GB

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).

(71) Applicant (*for all designated States except US*): ABBOTT
LABORATORIES [US/US]; Dept. 377 Bldg. AP6D-2,
100 Abbott Park Road, Abbott Park, IL 60064-6050 (US).

Published:

— Without international search report and to be republished
upon receipt of that report.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): GRAY, Elspeth, J.
[GB/GB]; 3 Henbane Close, Weaving, Maidstone, Kent

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 00/72820 A2

(54) Title: INJECTABLE ANESTHETIC FORMULATION

(57) Abstract: An injectable anesthetic formulation. The formulation contains a halogenated anesthetic in an amount not greater than approximately 24 % v/v of the formulation and an emulsification adjuvant in an amount from approximately 8 % to approximately 32 % v/v of the formulation. In addition, the formulation contains lecithin in an amount from approximately 1.2 % to approximately 2.4 % w/v of the formulation and a co-emulsifier in an amount not greater than approximately 1 % w/v of the formulation.

INJECTABLE ANESTHETIC FORMULATION

Technical Field of the Invention

5 The field of the present invention is anesthetics. More particularly, this invention pertains to an injectable anesthetic formulation.

Background of the Invention

10 Inhalation anesthetics such as isoflurane and sevoflurane are commonly used for anesthetizing patients for medical procedures. Although inhalation anesthetics are suitable for many medical procedures, they do have certain disadvantages. For example, induction of anesthesia by inhalation can be relatively slow in some patients. Further, the use of inhalation anesthetics requires the patient to breathe the anesthetic using a gas containment mask. The wearing of such a containment mask can be upsetting for some patients, particularly children. For these and other reasons, rapid anesthetic induction is
15 commonly performed by intravenous injection using relatively short acting agents such as propofol. Inhalation anesthetics are then used to maintain the anesthetized condition.

20 Inhalation anesthetics such as isoflurane and sevoflurane generally have been deemed unsuitable for parenteral administration due to their low aqueous solubility, thereby making it difficult to formulate them for intravenous administration, i.e., their low solubility results in unacceptably large dose volumes.

25 The need for a suitable formulation for injection has been recognized in the art. For example, U.S. Patent No. 5,637,625 discloses a phospholipid-coated, microdroplet propofol formulation. The disclosed formulation is devoid of fats and triglycerides so that the formulation provides sedation without fat overload. In addition, the formulation is free of nutrients capable of supporting bacterial growth, thereby providing the formulations with an increased shelf life. In
30 addition, the use of lecithin-coated microdroplets of methoxyflurane was

-2-

described in "Pharmacokinetics of Methoxyflurane After its Intra-dermal Injection as Lecithin-coated Microdroplets," published in J. Controlled Release (1989), 9(1), 1 - 12. However, neither of these disclosures suggests the possibility of using an emulsion formulation of an inhalation anesthetic.

5

Summary of the Invention

The present invention is directed to an injectable anesthetic formulation. In a first embodiment of the present invention, the formulation contains a halogenated anesthetic in an amount not greater than approximately 24% v/v of the formulation and an emulsification adjuvant in an amount from approximately 8% to approximately 32% v/v of the formulation. The formulation further contains lecithin in an amount from approximately 1.2% to approximately 2.4% w/v of the formulation and a co-emulsifier in an amount not greater than approximately 1% w/v of the formulation.

15

Detailed Description of the Invention

Although the present invention has been described herein in connection with certain exemplary and preferred embodiments, it will be appreciated by one of ordinary skill that various modifications can be made to the invention without departing from the scope of the invention, such scope being defined by the appended claims.

The anesthetic formulations of the present invention have use in inducing maintaining anesthesia in humans and animals. The formulations include a halogenated volatile anesthetic having a boiling point between approximately 20° and approximately 60° C. Such halogenated volatile anesthetics include, but are not necessarily limited to, desflurane, isoflurane, enflurane, halothane, and sevoflurane. Each of these anesthetics is well-known in the art. Although the examples set forth herein disclose formulations containing isoflurane, it is to be understood that any halogenated anesthetic having the desired boiling point can be used in the formulations of the present invention.

30

-3-

The formulations of the present invention further include an emulsification adjuvant such as soybean oil. Those of ordinary skill in the art will appreciate that other emulsification adjuvants having the characteristics of soybean oil can be used without departing from the spirit and scope of the present invention.

It has been found that a minimum ratio of 1 part emulsification adjuvant to 3 parts anesthetic is required in order to provide a stable emulsion. Further, it has been found preferable to provide an anesthetic formulation in which the total volume of dispersed phase, i.e., anesthetic and emulsification adjuvant, in the anesthetic formulation is below approximately 32% v/v in order to ensure that the viscosity of the resulting anesthetic formulation is acceptable for injection. In a preferred embodiment of the anesthetic formulation of the present invention, the halogenated anesthetic is present in an amount not greater than approximately 24% v/v while the emulsification adjuvant is present in an amount between approximately 8% and approximately 32% v/v.

The anesthetic formulation of the present invention further includes an emulsifier such as lecithin. Those of ordinary skill in the art will appreciate that other emulsifiers having the characteristics of lecithin can be used without departing from the spirit and scope of the present invention. The emulsifier is preferably present in an amount between approximately 0.6% and approximately 2.4% w/v. It has been found that emulsifier levels between approximately 1.2% and approximately 2.4% w/v are more preferable, and that emulsifier levels between approximately 1.8% and approximately 2.4% are most preferable in connection with the anesthetic formulation of the present invention.

The anesthetic formulation of the present invention further includes a co-emulsifier. An example of a co-emulsifier useful in connection with the anesthetic formulation of the present invention is a polyoxypropylene/polyoxyethylene block copolymer having a formula $\text{HO}(\text{C}_2\text{H}_4\text{O})_b(\text{C}_3\text{H}_6\text{O})_a(\text{C}_2\text{H}_4\text{O})_b\text{H}$ where a is an integer such that a molecular weight represented by a polyoxypropylene portion of the copolymer is between

-4-

approximately 900 to 15000, and b is an integer such that a molecular weight represented by a polyoxyethylene portion of the copolymer constitutes between approximately 5% and 90% of the copolymer. Those of ordinary skill in the art will appreciate that other co-emulsifiers having the characteristics of a polyoxypropylene/polyoxyethylene block copolymer can be used without departing from the spirit and scope of the present invention. In one embodiment of the present invention, poloxamer 188 is used as a co-emulsifier. The co-emulsifier is preferably present in an amount not greater than approximately 1% w/v, as explained in greater detail below, and more preferably in an amount not greater than approximately 0.96%.

It has been discovered that at a total emulsifier level (i.e., emulsifier content plus co-emulsifier content) of 1.8% w/v, a ratio of 8 parts of lecithin to 2 parts of poloxamer 188 provided desirable results in a 20% v/v isoflurane formulation due to an apparent reduction in droplet size and an increased resistance to creaming. Creaming is a form of emulsion instability well known in the art. However, it has been discovered that no stability benefits are obtained by the inclusion of poloxamer 188 in a 10% v/v isoflurane formulation. Accordingly, certain formulations in accordance with the present invention need not include a co-emulsifier such as poloxamer 188. Accordingly, as used herein, the term "in an amount not greater than" is intended to include the complete absence of a co-emulsifier from the anesthetic formulation of the present invention.

The anesthetic formulation of the present invention may further include a tonicifier such as glycerol. The tonicifier is used to adjust the tonicity of the anesthetic formulation to the tonicity of the patient's blood plasma. In a preferred embodiment of the anesthetic formulation of the present invention, the tonicifier is present in an amount between approximately 1% and approximately 4% of the formulation.

The anesthetic formulation of the present invention may also include a pH adjustor in an amount sufficient to adjust the pH of the formulation to between

-5-

approximately 6 and approximately 9, thereby making it suitable for injection and also for optimizing the stability of the emulsifier. A variety of known pH adjustors such as sodium hydroxide can be used in connection with the formulation of the present invention.

5 The preferred anesthetic formulation of the present invention further includes a vehicle for injection in a quantity sufficient for injection of the anesthetic formulation. Water can be used as the vehicle for injection.

 The following examples are provided for the purpose of providing a further understanding of the anesthetic formulations of the present invention and are
10 not intended to be limiting of the invention claimed in the appended claims.

Example 1:

 A 10% v/v formulation of isoflurane was prepared. Each 100 ml of the resulting anesthetic formulation contained:

15

isoflurane	10 ml
soybean oil	10 ml
glycerol	2.5 g
lecithin	1.8 g
20 distilled water	q.s.

 The soybean oil used in this example was winterized.

Example 2:

A 20% v/v formulation of isoflurane was prepared. Each 100 ml of the resulting anesthetic formulation contained:

5	isoflurane	20 ml
	soybean oil	10 ml
	glycerol	2.5 g
	lecithin	1.6 mg
	poloxamer 188	0.18 g
10	distilled water	q.s.

The soybean oil used in this example also was winterized. A pH adjustor (0.1 M sodium hydroxide) was added to adjust the pH of the resulting anesthetic formulation to between approximately 8 and approximately 9 prior to
15 autoclaving of the resulting formulation.

Anesthetic formulations prepared in accordance with the present invention are suitable for terminal sterilization by autoclaving, e.g., heating to a temperature of approximately 121° C for approximately 15 minutes. This characteristic of the anesthetic formulations of the present inventions obviates
20 the need for sterile processing.

Although the present invention has been described herein in conjunction with certain preferred embodiments and examples, it will be appreciated that certain modifications to the anesthetic formulation of the present invention can be made without departing from the intended spirit and scope of the present
25 invention which is defined by the appended claims.

-7-

WHAT IS CLAIMED IS:

1. An injectable anesthetic formulation comprising:
a halogenated volatile anesthetic in an amount not greater than approximately 24% v/v of said formulation;
an emulsification adjuvant in an amount from approximately 8% to approximately 32% v/v of said formulation;
lecithin in an amount from approximately 1.2% to approximately 2.4% w/v of said formulation; and
a co-emulsifier in an amount not greater than approximately 1% w/v of said formulation.
2. An injectable anesthetic formulation in accordance with Claim 1, wherein said halogenated anesthetic is selected from a group consisting of desflurane, isoflurane, enflurane, halothane, and sevoflurane.
3. An injectable anesthetic formulation in accordance with Claim 1, wherein said halogenated anesthetic is isoflurane.
4. An injectable anesthetic formulation in accordance with Claim 1, wherein said co-emulsifier is a polyoxypropylene/polyoxyethylene block copolymer.
5. An injectable anesthetic formulation in accordance with Claim 4, wherein said co-emulsifier is poloxamer 188.
6. An injectable anesthetic formulation in accordance with Claim 4, wherein said co-emulsifier has a formula:
$$\text{HO}(\text{C}_2\text{H}_4\text{O})_b(\text{C}_3\text{H}_6\text{O})_a(\text{C}_2\text{H}_4\text{O})_b\text{H}$$
wherein a is an integer such that molecular weight represented by a

-8-

- 5 polyoxypropylene portion of said copolymer is between approximately 900 to 15000, and b is an integer such that a molecular weight represented by a polyoxyethylene portion of said copolymer constitutes between approximately 5% and 90% of said copolymer.

7. An injectable anesthetic formulation in accordance with Claim 1, wherein said emulsification adjuvant is soybean oil.

8. An injectable anesthetic formulation in accordance with Claim 1, wherein said formulation further comprises glycerol in an amount of between approximately 1% to approximately 4% w/v of said formulation.

9. An injectable anesthetic formulation in accordance with Claim 1, wherein said formulation further comprises water.

10. An injectable anesthetic formulation in accordance with Claim 1, wherein said formulation further comprises a pH adjustor.

11. An injectable anesthetic formulation in accordance with Claim 10, wherein said pH adjustor is sodium hydroxide.

12. An injectable anesthetic formulation comprising:
a halogenated anesthetic in an amount not greater than approximately 24% v/v of said formulation;
an emulsification adjuvant in an amount from approximately 8% to
5 approximately 32% v/v of said formulation;
lecithin in an amount from approximately 1.2% to approximately 2.4% w/v of said formulation; and
a co-emulsifier in an amount not greater than approximately 1% w/v of said formulation;

-9-

10 a quantity of glycerol; and
 a quantity of a pH adjustor sufficient to adjust a pH of said
formulation to between approximately 6 and approximately 9.


13. An injectable anesthetic formulation in accordance with
Claim 12, wherein said halogenated anesthetic is selected from a group
consisting of isoflurane, enflurane, halothane, and sevoflurane.

14. An injectable anesthetic formulation in accordance with
Claim 12, wherein said halogenated anesthetic is isoflurane.

15. An injectable anesthetic formulation in accordance with
Claim 1, wherein said co-emulsifier is a polyoxypropylene/polyoxyethylene block
copolymer.

16. An injectable anesthetic formulation in accordance with
Claim 15, wherein said co-emulsifier is poloxamer 188.

17. An injectable anesthetic formulation in accordance with
Claim 15, wherein said co-emulsifier has a formula:



 wherein a is an integer such that molecular weight represented by a
5 polyoxypropylene portion of said copolymer is between approximately 900 to
15000, and b is an integer such that a molecular weight represented by a
polyoxyethylene portion of said copolymer constitutes between approximately 5%
and 90% of said copolymer.

18. An injectable anesthetic formulation in accordance with
Claim 12, wherein said emulsification adjuvant is soybean oil.

-10-

19. An injectable anesthetic formulation in accordance with Claim 12, wherein glycerol is present in an amount of between approximately 1% to approximately 4% w/v of said formulation.

20. An injectable anesthetic formulation in accordance with Claim 1, wherein said formulation further comprises water in an amount sufficient for injection of said formulation

21. An injectable anesthetic formulation in accordance with Claim 12, wherein said pH adjustor is sodium hydroxide.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number
WO 00/72820 A3

(51) International Patent Classification⁷: A61K 9/107,
31/08, A61P 23/00

Grace Cottage, The Street, Hartlip, Kent ME9 7TG
(GB). WITHERS, Brian, C. [GB/GB]; 21 Sandy Mount,
Bearstead, Maidstone, Kent ME14 4PJ (GB).

(21) International Application Number: PCT/US00/14502

(74) Agents: WOODWORTH, Brian, R. et al.; Dept. 377
Bldg. AP6D-2, 100 Abbott Park Road, Abbott Park, IL
60064-6050 (US).

(22) International Filing Date: 25 May 2000 (25.05.2000)

(25) Filing Language: English

(81) Designated States (*national*): AU, CA, JP, US.

(26) Publication Language: English

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).

(30) Priority Data:
9912446.3 27 May 1999 (27.05.1999) GB

Published:

— With international search report.

(71) Applicant (*for all designated States except US*): ABBOTT
LABORATORIES [US/US]; Dept. 377 Bldg. AP6D-2,
100 Abbott Park Road, Abbott Park, IL 60064-6050 (US).

(88) Date of publication of the international search report:
5 April 2001

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): GRAY, Elspeth, J.
[GB/GB]; 3 Henbane Close, Weaving, Maidstone, Kent
ME14 5UW (GB). HORDER, Rodney, L. [GB/GB];

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 00/72820 A3

(54) Title: INJECTABLE ANESTHETIC FORMULATION

(57) Abstract: An injectable anesthetic formulation. The formulation contains a halogenated anesthetic in an amount not greater than approximately 24 % v/v of the formulation and an emulsification adjuvant in an amount from approximately 8 % to approximately 32 % v/v of the formulation. In addition, the formulation contains lecithin in an amount from approximately 1.2 % to approximately 2.4 % w/v of the formulation and a co-emulsifier in an amount not greater than approximately 1 % w/v of the formulation.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/14502

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/107 A61K31/08 A61P23/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, WPI Data, PAJ, EPO-Internal, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 127, no. 1, 7 July 1997 (1997-07-07) Columbus, Ohio, US; abstract no. 683r, M.A. RIFKY ET AL.: "halothane and isoflurane in intralipid as intravenous anesthetics to dogs" page 689; column 1; XP002154520	1-3, 7-14, 18-21
Y	abstract & ZAGAZIG J. PHARM. SCI., vol. 55, no. 1, 1996, pages 132-137, --- -/--	4-6, 15-17



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

4 December 2000

Date of mailing of the international search report

22/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Benz, K

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/14502

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BPI: "Rote Liste 1998" 1998 , ECV EDITIO CANTOR , AULENDORF (DE) XP002154519 229290 page 52160 -page 52162 Intralipid -----	1-3, 7-14, 18-21
Y	EP 0 391 369 A (YISSUM RE. DEV. COMP.) 10 October 1990 (1990-10-10) page 7 -page 8; example 1 -----	4-6, 15-17
X	US 4 073 943 A (WRETLIND ET AL.) 14 February 1978 (1978-02-14) column 10, line 30 - line 36 -----	1
X	EP 0 211 258 A (ABBOTT LABORATORIES) 25 February 1987 (1987-02-25) page 7, line 32 -page 8, line 1 page 16 -page 17; example 1 -----	1-3,7-9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/14502

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 391369	A	10-10-1990	IL 89856 A	13-05-1993
			IL 93558 A	27-11-1995
			AT 110563 T	15-09-1994
			AU 614465 B	29-08-1991
			AU 5292790 A	11-10-1990
			CA 2013755 A,C	05-10-1990
			DE 69011922 D	06-10-1994
			DE 69011922 T	12-01-1995
			JP 2083211 C	23-08-1996
			JP 2290809 A	30-11-1990
			JP 7121857 B	25-12-1995
			US 5364632 A	15-11-1994
			KR 9300044 B	06-01-1993
US 4073943	A	14-02-1978	NONE	
EP 211258	A	25-02-1987	AU 589430 B	12-10-1989
			AU 6021486 A	05-02-1987
			DK 354886 A	30-01-1987
			ES 556056 D	01-10-1987
			ES 8708185 A	16-12-1987
			GR 861462 A	02-10-1986
			JP 62029511 A	07-02-1987
			KR 9003557 B	21-05-1990
			ZA 8604031 A	28-01-1987